Hibsago (Bepirovirsen)

Bepirovirsen is a medicine used to treat long-term hepatitis B infection, alongside the usual hepatitis B pills. It is given as a shot under the skin. It works by blocking the virus's instructions for making its proteins, which helps the body bring the infection under control.

Brand names:Hibsago
Medication

What people taking Hibsago (Bepirovirsen) report

Every report comes from a Lived member, sent anonymously.

Have you tried Hibsago (Bepirovirsen) for Chronic Hepatitis B?

NameHow it went

About Hibsago (Bepirovirsen)

What It's For

Bepirovirsen, sold as Hibsago, is an injectable medicine for chronic hepatitis B, a long-term infection of the liver with the hepatitis B virus. It is added to the daily antiviral pills most people with hepatitis B already take, such as entecavir or tenofovir. It does not replace them. Those pills, called nucleoside or nucleotide analogs, keep the virus from multiplying, but they rarely clear the infection, so most people take them for years. Bepirovirsen is given as a single fixed course with a different goal: a functional cure. That means the virus stays undetectable in the blood and its outer protein, HBsAg (hepatitis B surface antigen), disappears from blood tests, and both stay that way after all hepatitis B treatment has stopped. It is not a guaranteed cure. In trials, about 1 in 5 people reached this goal. It was approved in the US in 2026 for a specific group: adults without cirrhosis (scarring of the liver) who have taken antiviral pills for at least 6 months, whose virus level in the blood (HBV DNA) is suppressed, and whose HBsAg level is 3,000 IU/mL or lower on an FDA-authorized test. That HBsAg number matters because people starting with lower levels were more likely to respond.

How It Works

The hepatitis B virus keeps a stable copy of its genetic material inside infected liver cells, and some of it can become built into the cells' own DNA. Antiviral pills block the step where the virus copies itself, but these stored templates keep sending out instructions, called messenger RNA (mRNA), that tell the cell to make viral proteins, including HBsAg. Bepirovirsen is an antisense oligonucleotide: a short, lab-made strand of genetic material built to match a stretch found in all of the virus's mRNA, whether it comes from the stored copy or from virus built into the cell's DNA. When bepirovirsen attaches, the cell's own enzymes break the message down, so the cell makes less viral protein and less virus. Lowering HBsAg appears to give the immune system a better chance to control the infection. Many people have a temporary rise in liver enzymes during treatment that comes just after or alongside a fall in HBsAg, which suggests the immune system is attacking infected cells. Studies also suggest bepirovirsen stimulates the body's built-in immune defenses directly.

Dosage & Administration

Bepirovirsen comes in 150 mg prefilled syringes injected under the skin. Each dose is 300 mg, given as two injections one right after the other. For the first 2 weeks, doses are given twice a week, 3 or 4 days apart. From week 3 through week 24, doses are given once a week on the same day. Treatment stops after 24 weeks, and the antiviral pills continue throughout and afterward. The first dose is given under a clinician's supervision. After training, a patient or caregiver may give the injections at home, as long as blood tests continue. Injections go into the thigh or abdomen, staying 2 inches away from the belly button; a caregiver can also use the outer upper arm. Rotate injection sites from one week to the next, keep the two injections at least 2 inches apart, and never inject into skin that is tender, bruised, red or hard. In the trials, one person who did not rotate sites had a serious reaction in which part of the fatty tissue inside the abdomen lost its blood supply. Let the syringes sit at room temperature for at least 30 minutes before injecting, and do not shake them. If a dose is missed, give it as soon as possible, unless the next dose is due in less than 3 days; in that case skip it and stay on schedule. The doctor may stop treatment early if HBsAg has not fallen to nearly undetectable levels by week 12.

Side Effects

The most common side effects are injection site reactions, fever, tiredness and headache. Some people also have flu-like symptoms after doses. The FDA's most serious warning, a boxed warning, covers two risks. The first is liver flares. ALT is a liver enzyme that rises when liver cells are inflamed, and large ALT rises are common during treatment, usually between weeks 5 and 10. Most cause no symptoms and start settling within about 2 weeks, but some are very large, and a few came with a rise in bilirubin (a sign the liver is under strain). This is why liver blood tests are checked so often, and why treatment may be paused, given at a lower dose or stopped. Call the care team right away for abdominal discomfort, dark urine or yellowing of the skin or eyes. The second is low platelets, the blood cells that help blood clot. Most people's platelet counts drift down gradually during treatment, and a few people had sudden, severe drops that can be life-threatening. Call the care team right away for signs of bleeding: easy bruising or tiny red or purple spots on the skin; bleeding gums, nosebleeds or other bleeding that is unusual or will not stop; blood in the urine or stool, black stools, or vomiting or coughing up blood; or heavier periods than usual. A stiff neck or an unusual severe headache can signal bleeding inside the head and needs medical care right away. Treatment is paused until a platelet count is checked. Kidney function also tends to dip during treatment. This shows up on blood tests rather than as symptoms and usually recovers within a few months of stopping. Less often, the drug triggers immune reactions: tell the care team about flu-like symptoms together with a purplish rash on the legs, itchy red patches of skin or joint pain. Rare serious immune reactions, including the immune system attacking platelets or red blood cells, have occurred.

Interactions & Warnings

Bepirovirsen should not be used by people with cirrhosis or sudden liver impairment, or whose platelet count is already below 100,000 per microliter before starting (a normal adult count is 150,000 to 450,000). It is not recommended for people who also have hepatitis D, a virus that only infects people who have hepatitis B, because liver flares may be worse. Doctors weigh the risks more carefully for organ transplant recipients, people with autoimmune hepatitis, lupus, rheumatoid arthritis, vasculitis (inflamed blood vessels) or kidney disease, and older adults or anyone with a bleeding disorder. Because of the platelet risk, bleeding needs closer watching in people who also take blood thinners such as warfarin or apixaban (Eliquis), antiplatelet medicines such as aspirin or clopidogrel (Plavix), or other treatments that can lower platelets, such as some cancer chemotherapy. Medicines that can strain the kidneys need the same caution, including anti-inflammatory pain relievers such as ibuprofen (Advil, Motrin) and naproxen (Aleve). Tell the prescriber and pharmacist about all of these, including over-the-counter pain relievers, before starting. Peginterferon alfa-2a, an injectable hepatitis treatment that boosts the immune system, should not be combined with bepirovirsen. The biggest risk after the course is stopping the antiviral pills too soon. Hepatitis B can flare severely when all treatment stops, so stopping the pills is a decision for the doctor, followed by frequent blood tests for at least a year. People who take these pills to treat HIV as well as hepatitis B must not stop them unless their HIV provider says to. It is not known whether bepirovirsen prevents passing hepatitis B to others, so the usual precautions still apply. There is too little information on use in pregnancy or breastfeeding to know the risks, and it has not been studied in children.

What to Expect

Expect a lot of blood tests. Before starting, the care team measures HBsAg, virus level, liver tests, platelets and kidney function. During the 24 weeks, platelets are checked weekly, liver tests weekly through week 12 and then every other week, and kidney function every other week, with follow-up tests after the course if anything was abnormal. Pauses for lab changes are not unusual and do not necessarily mean the treatment has failed. In two large trials of adults without cirrhosis, about 1 in 5 people who received bepirovirsen (19% to 20%) reached functional cure 24 weeks after stopping all hepatitis B treatment, compared with none on placebo. Results depended on the starting HBsAg level and the virus's genetic type (genotype): response rates ranged from about 15% to 28% across the common genotypes, and fell below 10% for genotypes B and C when HBsAg started above 1,000 IU/mL. Most people will not reach functional cure and will simply continue their antiviral pills as before. After the 24-week course, the pills continue for at least another 24 weeks. Stopping them can then be considered for people whose virus and HBsAg are undetectable, whose ALT is no more than twice the normal upper limit, who test negative for another viral marker called HBeAg (hepatitis B e-antigen), and who do not need the pills for HIV. Because the drug is new, how long a functional cure lasts beyond the trials' follow-up is still being learned, so ongoing monitoring remains part of care.

Questions to Ask Your Doctor

  1. 1.Based on my HBsAg level and virus genotype, how likely am I to reach a functional cure with bepirovirsen?
  2. 2.How will we fit weekly blood tests into the 24 weeks, and what results would lead us to pause or stop?
  3. 3.Do any of my medicines, such as blood thinners or aspirin, or my other health conditions make this riskier for me?
  4. 4.If I do reach a functional cure, how would we decide whether to stop my antiviral pills, and how would I be monitored afterward?
  5. 5.If I do not respond, what does that mean for my long-term hepatitis B care?

Last reviewed • Oct 2026

Educational content, not medical advice.